Table 10.

Ongoing clinical trials of fibrinolytic therapy in COVID-19

NCT number	Study name	Interventions	Sponsor
NCT04357730	Fibrinolytic Therapy to Treat ARDS in the Setting of COVID-19 Infection	Phase 2a trial comparing 50 mg and 100 mg doses of alteplase	Denver Health and Hospital Authority (USA)
NCT04356833	Nebulised rtPA for ARDS Due to COVID-19 (PACA)	Phase 2 trial evaluation nebulized tissue plasminogen activator in COVID-19 ARDS	University College London (UK)

Abbreviations: ARDS acute respiratory distress syndrome, COVID-19 coronavirus disease 2019, mg milligrams, Rt-PA recombinant tissue plasminogen activator